Sign in
CompletedNo phase

Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases

Key facts

Who runs it
GCS Ramsay Santé pour l'Enseignement et la Recherche
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
21 people enrolled
Started
27 Jun 2023
Ended
25 Jul 2025
Type of study
Interventional
Treatments tested
  • biological samples (blood test and lumbar puncture)
Record updated
24 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patient aged 18 or over
  • Patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision (contrast enhancement of at least 1 cm)
  • Patient able to understand the information related to the study and to read the information leaflet
  • Patient having signed a written informed consent to participate in the study

Who cannot take part

  • Patient with a medical contraindication to surgery and anesthesia
  • Patient whose anatomical location of the cerebral metastasis contraindicates wide resection
  • Patient with a contraindication to performing a lumbar puncture
  • Pregnant, parturient or breastfeeding women
  • Patient participating in another clinical trial, or in a period of exclusion from another clinical trial
  • Patient under guardianship or curatorship, or under a regime of deprivation of liberty
  • Patient not benefiting from a social security scheme

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to determine in brain metastases and according to feasibility in liquid biopsies:

Read full original descriptionShow less

* Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing; * The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome; * Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.

The group in the trial

  • brain metastases from solid cancerOther group

    Excision of the cerebral metastasis

    Treatment: biological samples (blood test and lumbar puncture)

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 November 2025